In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Sanjay Kakkar, CEO of San Francisco Bay-based start-up Tranquis Therapeutics. The company focuses on neurodegenerative diseases, an area where significant unmet medical need remains and that has presented the life sciences sector with major challenges for many years. Undaunted, Tranquis Therapeutics has successfully raised $30m in series A for their lead compound. In this interview Sanjay shares the milestones involved in both the development of their compelling compounds that are set to revolutionise the space, as well as the areas that attracted and intrigued their supportive investors. Mike and Sanjay also look to the future and touch on upcoming milestones such as clinical trials and possible commercialisation partnerships. Hosted on Acast. See acast.com/privacy for more information.